Exciting news in anxiety treatment! The FDA has granted breakthrough therapy designation to MM120, a novel LSD-based treatment for generalized anxiety disorder. Phase 2 trials showed that a single oral dose led to meaningful reductions in anxiety symptoms lasting for weeks LifeStance Health, with Phase 3 trials currently underway.
What makes this particularly promising is that it represents the first entirely new class of anxiety medication in nearly two decades. Unlike traditional medications that require daily use, MM120’s primary mechanism is to promote neuroplasticity in the brain, potentially altering negative thought patterns UCSF.
While this treatment is still in trials and not yet available, it represents hope for those who haven’t found relief with current options. As always, evidence-based treatments like CBT and exposure therapy remain highly effective for most people with anxiety disorders.
If you’re struggling with anxiety, please reach out. Together, we can find the right approach for you.
Source: UCSF News, LifeStance Health, 2024-2025
